Categories
Archives
Receive Email Updates
-
-
-
Certified Licensing Professionals, Inc., 2021 
Disclaimer
This blog, Patents4Life, does not contain legal advice and is for informational purposes only. Its publication does not create an attorney-client relationship nor is it a solicitation for business. This is the personal blog of Warren Woessner and does not reflect the views of Schwegman Lundberg & Woessner, or any of its attorneys or staff. To the best of his ability, the Author provides current and accurate information at the time of each post, however, readers should check for current information and accuracy.
-
- About Me
Warren D. Woessner
Pages
Archives
Tag Archives: Ariad v. Lilly
Supreme Court Declines To Review “New And Improved” Written Description Requirement
On Tuesday, the Supreme Court denied Centocor’s (now “Janssen”) petition for cert. and so let stand a ruling that Centocor’s patents on humanized monoclonal antibodies (covering Abbott’s Humira) are invalid for failure to meet the written description requirement (WDR) of … Continue reading
Update, Partner and Innovate — AUTM Eastern Regional Meeting
I will be on a panel entitled “Kicking the Hornet’s Nest – Patenting Early Stage Technology” at the AUTM Eastern Regional Meeting in Baltimore (May 24th). I will be joined by Esther Kepplinger, Director of Patent Operations at Wilson Sonsini … Continue reading
Posted in Conferences and Classes
Tagged Ariad v. Lilly, AUTM, DNA, Patent Law, Warren Woessner
Leave a comment
Happy Birthday Patents4Life – We Are 2!
Now some of them are not yet carved in judicial stone, being at various stages of appeal, but the sum of KSR, Bilski (well, I guess it was more pro-patent than the strict M or T test it replaced with … Continue reading
Posted in About SLW
Tagged Ariad, Ariad v. Lilly, Bilski, biotechnology, biotechnology law, biotechnology news, Federal Circuit, intellectual property, ip, IP law tools, KSR, Kubin, Lilly, Myriad, Patent Law, patents, Pharmaceutical law, Prometheus v. Mayo, stem cells, Supreme Court, Warren Woessner
1 Comment
Director Kappos Comments on Ariad v. Lilly
USPTO David Kappos recently posted a comment on the Fed. Cir. decision in Ariad v. Lilly in which he noted that the Fed. Cir. held that broad functional claims (presumably mechanism-of-action claims) must be supported by sufficient species (read “working examples”). While … Continue reading
Posted in Written Description Requirements (WDR)
Tagged Ariad v. Lilly, David Kappos, Patent Law, patents, USPTO, Warren Woessner
Leave a comment